Sun Pharma Launches Drizalma Sprinkle (duloxetine delayed-release capsules) for Neuro-Psychiatric and Pain Disorders in the US

Sun Pharma Launches Drizalma Sprinkle (duloxetine delayed-release capsules) for Neuro-Psychiatric and Pain Disorders in the US

Shots:

  • The launch of Drizalma Sprinkle expands Sun Pharma’s portfolio of an alternative formulation designed for patients with swallowing difficulties, following its Ezallor Sprinkle (Rosuvastatin) and Kapspargo Sprinkle (metoprolol succinate) extended-release capsules, marking it as the third product of Sun Pharma’s portfolio
  • In July’2019, the US FDA has approved Drizalma Sprinkle and is an important milestone for patients with difficulty in swallowing as it facilitates treatment of common neuropsychiatric disorders while preserving the quality of the medicine
  • Drizalma Sprinkle (20mg, 30mg, 40mg, and 60mg) is a serotonin and norepinephrine reuptake inhibitor (SNRI) and is the only formulation that can be swallowed whole, sprinkled on applesauce or administered via nasogastric tube

Click here to­ read full press release/ article | Ref: Business Wire | Image: Coroflot